Novasep, a supplier of services and technologies for the life sciences industry, has finalised the set-up of its new synthesis laboratory and kilo lab at its US facility in Boothwyn, PA.
The firm says production of kilogram scale batches of synthetic molecules for biological testing and preclinical trials has begun on schedule.
'Drug developers in the US are responding positively to our extended CMO services that support their early stage programmes,' said Andrew Brennan, General Manager at Novasep’s US operations. 'The opening day was held with our customers and Novasep’s scientific board member Prof. Alois Fürstner, who made an inspiring presentation on catalysis. This was a great way to kick-off the opening of our new lab.'
The firm says the lab's proximity to its US experts will help to secure and speed up customers’ projects.
Drug developers in the US are responding positively to our extended CMO services that support their early stage programmes
'The partnerships that Novasep is building with US companies will promote future development and commercial supply agreements to keep up with the fast growing US pharmaceutical market,' said Thierry Van Nieuwenhove, Synthesis BU President.
The Boothwyn facility is equipped with jacketed reactors ranging from 100mL to 50L in size and with a 35L filter dryer for isolation of kilogram quantities of compound. The laboratory extension features all the necessary equipment for standard and cryogenic chemistry.
In terms of purification services, the lab provides North American customers with the complete portfolio of Novasep preparative chromatography technologies, such as HPLC (Hipersep) and SFC (Supersep). In addition, it has all the required analytical tools for process research and development (HPLC, HPLC/MS, GC, GC Headspace, UPLC, UPLC/MS, etc.), including a calorimetric reactor for preliminary process safety testing.
